Immunic(IMUX) Prnewswire·2025-02-20 12:30Core Insights - IMU-856 shows potential as an oral treatment option for weight management, demonstrating a dose-dependent increase in GLP-1 levels and reduction in body weight gain and food consumption [1][2][3] Clinical Trial Findings - A post hoc analysis from a phase 1b clinical trial in celiac disease patients revealed a statistically significant increase in GLP-1 levels, with a dose-dependent increase of up to 250% compared to placebo [2][3] - The trial involved a small patient population, with 11 in the placebo group and 13 each in the 80 mg and 160 mg IMU-856 groups [2] - Preclinical studies indicated a reduction in body weight gain by up to 40% in a dose-dependent manner, linked to decreased food intake [2][3] Mechanism of Action - IMU-856 targets SIRT6, a protein involved in intestinal barrier function and regeneration, which may enhance the function of enteroendocrine cells that produce GLP-1 [2][7] - The compound has shown positive results in histology, disease symptoms, biomarkers, and nutrient absorption in celiac disease patients [7] Market Potential - The obesity treatment market is projected to exceed $170 billion globally by 2031, indicating significant commercial potential for IMU-856 if further clinical trials confirm its efficacy [3] Company Overview - Immunic, Inc. is focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, with IMU-856 as a key candidate [8]